Alzheimer’s Treatment: Why Science Alone Isn’t Enough

Researchers have spent years chasing a cure for Alzheimer’s, focusing on how proteins called amyloid clump together in the brain. Back in the 1990s, scientists, including one leading expert, realized that these clumps might harm brain cells and trigger inflammation. At first, they thought fixing this problem would be quick and easy. But decades later, progress is finally happening—but not as fast as hoped. New drugs like Donanemab and Lecanemab can now remove some of those amyloid clumps. A recent study showed Lecanemab slows memory loss in early Alzheimer’s patients. Instead of stopping the disease completely, it only delays it by a few years. That’s still progress, but not the breakthrough everyone wanted.Not everyone agrees amyloid is the main cause. Some scientists believe focusing too much on it has slowed research. Even if it plays a role, other factors might be just as important. To make real progress, experts say we need better ways to spot Alzheimer’s early—like checking blood for clues, similar to how cholesterol predicts heart disease. Right now, these new drugs are expensive and hard to get. In the US, they’re approved, but in the UK, only private patients can try them. Finding the right patients is also tricky. Many people diagnosed with dementia actually have other types, not Alzheimer’s. Without better tests, treatments won’t reach the right people. The bigger issue? Governments aren’t spending enough on Alzheimer’s care. More money could help train doctors, improve early screening, and speed up research. Scientists are working on stronger drugs, but without political support, even the best treatments won’t help as many people as they should.